
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report: **May 20, 2008**

Corgenix Medical Corporation

(Exact Name of registrant as specified in its charter)

Nevada
(State or other jurisdiction
of incorporation)

000-24541
(Commission File Number)

93-1223466
(I.R.S. Employer
Identification No.)

11575 Main Street, Number 400
Broomfield, Colorado 80020
(Address, including zip code, of principal executive offices)

(303) 457-4345
(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting Material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 7.01 Regulation FD Disclosure

On May 20, 2008, Corgenix Medical Corporation management met with shareholders at its annual shareholders meeting. A copy of the presentation materials of the company's President and Chief Executive Officer and Chief Financial Officer that were used at that meeting is filed as Exhibit 99.1 hereto.

ITEM 8.01 Other Events

The 2007 annual meeting of the shareholders of Corgenix Medical Corporation was held at the company's corporate offices on May 20, 2008 at approximately 9:00 a.m. Mountain Time. At the meeting, the shareholders elected Dr. Luis R. Lopez, Mr. Douglass T. Simpson, Mr. Robert Tutag, Mr. C. David Kikumoto, Mr. Larry G. Rau, Mr. Dennis Walczewski and Mr. Stephen P. Gouze as directors of the company, approved the proposal to amend the company's Articles of Incorporation to increase Authorized Shares of Common Stock from 100 million to 200 million and ratified the appointment of Hein & Associates LLP as the company's independent public accountants for the fiscal year ending June 30, 2008. The company will disclose the voting detail regarding the proposals approved at the meeting in its upcoming annual filing.

ITEM 9.01 Financial Statements and Exhibits

- a) Not applicable.
- b) Not applicable.
- c) Not applicable.
- d) Exhibits:

99.1 Shareholder presentation material of the President and Chief Executive Officer and Chief Financial Officer of Corgenix Medical Corporation used on May 20, 2008.

Safe Harbor Statement

Statements in this report that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this report are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORGENIX MEDICAL CORPORATION

Date: May 20, 2008

By: /s/ Douglass T. Simpson
Douglass T. Simpson, President and Chief Executive Officer

Corgenix Medical Corporation
Annual Shareholder Meeting
May 20, 2008
PowerPoint Presentation

Slide 1 – Title Slide
Annual Meeting of the Shareholders
May 20, 2008

Slide 2 - Agenda

- Business Update
 - Review of Corporate Goals
 - Revenue Strategies
 - Review of Fiscal Year 2007 and Fiscal Year 2008 Year-to-Date Results
 - Financials
 - Key Events, Achievements and Disappointments
 - Fiscal Year 2008 Plan
 - Plan for 2009-2010

Slide 3 – Corporate Goals

- Financial Strength
- Consistent Growth in Revenues and Profitability
- Continued Improvement in Shareholder Liquidity
- Product Quality

Slide 4 - Revenue Strategies

- Financial Strength
- Consistent Growth in Revenues and Profitability
- Continued Improvement in Shareholder Liquidity
- Product Quality

Slide 5 – Strategic Alliances

(logos of strategic alliance companies)

Slide 6 - FY 2007 and FY 2008 YTD Statement of Operations

	<u>FY 2008</u>	<u>FY 2007</u>	<u>FY 2007</u>	<u>FY 2006</u>
	<u>9-mo ended 3/31/08</u>	<u>9-mo ended 3/31/07</u>	<u>FY ended 6/30/07</u>	<u>FY ended 6/30/06</u>
	<u>unaudited</u>	<u>unaudited</u>	<u>audited</u>	<u>audited</u>
Sales.....	\$ 6,455	\$ 5,391	\$ 7,368	\$ 6,636
Gross Profit.....	\$ 3,627	\$ 2,134	\$ 4,539	\$ 4,174
Op Inc (Loss).....	\$ 163	\$ (740)	\$ (858)	\$ 335
Net Loss.....	\$ (1,101)	\$ (2,081)	\$ (2,441)	\$ (1,586)
EBITDA.....	\$ 467	\$ (475)	\$ (496)	\$ 444

Slide 7 - FY 2007 and FY 2008 YTD Balance Sheet Highlights

	<u>At March 31, 2008</u>	<u>At June 30, 2007</u>	<u>At June 30, 2006</u>
	<u>(unaudited)</u>	<u>(audited)</u>	<u>(audited)</u>
Cash	\$ 1,652	\$ 1,324	\$ 3,118
Working Capital.....	\$ 3,254	\$ 2,070	\$ 4,205
Stockholder's Equity	\$ 4,401	\$ 2,993	\$ 4,691

Slide 8 – FY 2007 – Key Events of the Year

- July '06
 - Launched AspirinWorks in Europe
 - Expanded UK facility to meet growth plans
 - Submitted 510(k) for AspirinWorks
- August '06
 - First US patent for AspirinWorks issued
- February '07
 - Second US patent for AtherOx issued
- March '07
 - License for 100% of rights to AspirinWorks
- June '07
 - AspirinWorks receives 510(k) clearance

Slide 9 – FY 2007

- Accomplishments
 - Revenue for the year was another Company record – grew 11% to \$6.4 million
 - Major advancement in several important strategic programs
 - Expanded US and international distribution network
 - Received FDA clearance on AspirinWorks
 - Recovered from move into new HQ facility
 - New patents issued for AspirinWorks and AtherOx; additional patent applications filed
- Disappointments
 - Revenue level was not sufficient to achieve profitability
 - Expenses related to new facility increased significantly
 - Stock price languished

Slide 10 – FY 2008 Goals

- Continue revenue growth at accelerated rate
- Improvement in operating income, EBITDA and overall financial strength
- Get operating expenses under control
- Build foundation of market for AspirinWorks and generate meaningful revenue
- Advance science of AtherOx and prepare for market entry
- Move stock price and trading volumes to the next level
- Complete first phase of viral program and prepare for market entry in FY 2009
- Expand our delivery platform capability
- Enhance contract manufacturing business

Slide 11 – FY 2008 YTD – Key Events of the Year

- July '07
 - Announcement of new papers on AtherOx
 - Announcement of new papers on AspirinWorks
 - x-AtherOx 510(k) filed
- August '07
 - Update on AspirinWorks distribution including LabCorp
 - AspirinWorks available on internet
- October '07
 - Release of clinical data on Lassa virus program
 - Corgenix again wins 'Fast 50' award
- November '07
 - Clinical trial data on AtherOx released
- December '07
 - Sign research agreement with NIH for Hyaluronic Acid

Slide 12 - FY 2008 YTD – Key Events of the Year

- January '08
 - More publications on 'Aspirin Resistance'
 - Updated AspirinWorks distribution including Quest Diagnostics
- February '08
 - European patent issued for AspirinWorks
- March '08
 - Technology licensing agreement signed with Japanese government for inflammation bio-marker
- April '08
 - AspirinWorks collaboration with Randox for automated version of test
 - 510(k) clearance on x-AtherOx

Slide 13 - FY 2008 YTD Accomplishments

- Financials
 - 9-month revenues up 20% over prior year
 - on track for another record sales year
 - expenses under control
- AspirinWorks ELISA
 - product launched following May 2007 FDA clearance
 - made significant progress in building market infrastructure
 - revenues will exceed first-year revenues of any other Corgenix product
 - Initiated program for automated version of test

Slide 14 – FY 2008 YTD Accomplishments

- AtherOx
 - received FDA clearance on x-AtherOx
 - making solid advances in clinical studies of AtherOx product group
- Lassa virus program showing favorable clinical results

Slide 15 – FY 2008 YTD Disappointments

- Ramp up of AspirinWorks revenue lagging behind original projections
- Due to change in technology strategy, major contract manufacturing customer has reduced purchases; will be down \$200,000 from FY 2007 with impact in 3Q and 4Q and FY 2009
- Experienced some manufacturing problems in Q1 impacting COGS
- The medical products industry as a whole is being impacted by the slowing economy

Slide 16 – Plan for FY 2009 and FY 2010

- Continue double digit revenue growth; accelerate growth rate with contribution from new products
- Accelerate new product clearances from the FDA
- Retire last of convertible debt from 2005 financings
- Achieve positive and continuously improving operating income, net income and EBITDA
- Enhanced shareholder value
- Build on strategic partnerships
- Maintain superior quality system to ensure full regulatory compliance
- Expand delivery technology capabilities